Aarti Drugs (AARTIDRUGS) Fundamentals 2026 — P/E 19.3x, Revenue Analysis | SniperIQ
Aarti Drugs (AARTIDRUGS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹3,760 Crore, trading at ₹412.00 on the NSE. This SniperIQ fundamentals page covers Aarti Drugs's valuation (P/E 19.3x, P/B 2.4x), profitability (net margin 7.6%), revenue (₹2,565 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aarti Drugs's market cap?
Aarti Drugs (AARTIDRUGS) has a market capitalization of approximately ₹3,760 Crore, trading at ₹412.00 on the NSE. Market cap moves with the live share price.
What is Aarti Drugs's P/E ratio?
Aarti Drugs's trailing twelve-month P/E ratio is 19.3x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aarti Drugs?
Aarti Drugs runs a net profit margin of 7.6%, a gross margin of 32.9%, and an operating margin of 9.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aarti Drugs generate?
Aarti Drugs reported revenue of ₹2,565 Crore for fiscal year 2026, with net income of ₹195 Crore and earnings per share (EPS) of 21.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aarti Drugs pay a dividend?
Aarti Drugs offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Aarti Drugs financially healthy?
Aarti Drugs carries a debt-to-equity ratio of 0.37x and a current ratio of 1.59x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aarti Drugs a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aarti Drugs (AARTIDRUGS) the key facts are: market cap ₹3,760 Crore, P/E 19.3x, revenue ₹2,565 Crore, 52-week range 318.95-551.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aarti Drugs's full fundamentals live
Get Aarti Drugs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.